MedWatch

FDA gives Saniona candidate priority status

The US FDA has given biotech firm Saniona's drug candidate Tesomet priority status as an orphan drug for treating hypothalamic obesity. Earlier this year, Tesomet received the same priority status as a treatment for Prader-Willi syndrome.

Photo: Andrew Kelly/REUTERS / X02844

The US Food and Drug Administration FDA has given orphan drug priority status to Saniona's drug candidate Tesomet for treating hypothalamic obesity (HO), according to a press release on Monday.

"There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO," says Saniona Chief Medical Officer and Head of Clinical Development Rudolf Baumgartner in the press release.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs